Group 1 - The core viewpoint of the article highlights that Aimeike's financial performance in the first half of 2025 shows significant declines in revenue and profit, indicating challenges in the market [1][2] - Aimeike reported a revenue of 1.299 billion yuan for the first half of 2025, a year-on-year decrease of 21.59%, and a net profit of 789 million yuan, down 29.57% [1] - The company's cash flow from operating activities also decreased by 43.06% to 655 million yuan, reflecting a broader trend of declining financial health [1] Group 2 - In the second quarter of 2025, Aimeike's revenue fell by 25.11% to 636 million yuan, with net profit dropping 41.75% to 346 million yuan [1] - The report indicates that the medical beauty industry in China is experiencing a transformation from scale expansion to a focus on quality and effectiveness, driven by increased competition and consumer demand [2] - The market is seeing a notable differentiation between high-end and mass markets, with new injectable products becoming the focal point of the industry [2]